Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Lenard Lichtenberger
University of Texas Hlth Sci Ctr Houston, Department: Biology
Should you be removed from our database? Contact us at [email protected]. Read more below.
PLx Pharma, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Lichtenberger is co-founder, serves as a Scientific Advisory Board member, and holds equity in PLx Pharma, Inc. The company was formed to commercialize novel formulations of proven non-steroidal anti-inflammatory drugs that are safer for the gastrointestinal tract. The institution licenses intellectual property to PLx Pharma, Inc. and Dr. Lichtenberger participates in research related to the licensed technology.
Surfactant lipids and associated proteins in radiation-induced mucositis
Oral mucositis is perhaps the most severe oral side effect of radiation therapy for head and neck cancer, afflicting 30-70% of cancer patients and consists of painful inflammation and ulceration of the mucous membranes lining the oral cavity making it difficult to eat and speak and can lead to infections and in severe cases, infection. For many cancer patients, severe oral mucositis becomes limiting on the dosage and/or duration of radiation, requiring treatment modifications and compromises to prognosis and lack of compliance. In this proposal we will investigate the effects of radiation exposure either performed in the laboratory on mice or in the clinic on saliva from head and neck cancer patients before, during and after radiotherapy on salivary gland surfactant lipids and associated proteins with the goal of understanding their role in the pathogenesis of mucositis and the potential development of a novel therapy to prevent and/or ameliorate this condition.
Filed on May 19, 2017.
Tell us what you know about Lenard Lichtenberger's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Lenard Lichtenberger filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Lenard Lichtenberger | University of Texas Hlth Sci Ctr Houston | Conflict of Interest | PLx Pharma Inc. | $40,000 - $59,999 |
| Lenard Lichtenberger | University of Texas Hlth Sci Ctr Houston | Conflict of Interest | PLx Pharma Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.